Background. Prostaglandins can affect the vascular response and are locally produced in the peritoneal cavity. Prostaglandin inhibition in continuous ambulatory peritoneal dialysis (CAPD) patients during peritonitis using indomethacin intraperitoneally was found to decrease the intrinsic permeability to macromolecules. Methods. In the present study the effects of prostaglandin inhibition were studied during stable, uninfected CAPD. Two standard peritoneal permeability analyses (1.36% glucose) were performed in 10 stable CAPD patients within 1 week with and without addition of 12.5 mgul indomethacin. Furthermore, possible effects on the parameters of nitric oxide synthesis were determined. In ®ve other patients a high dose of indomethacin was tested. The night before the indomethacin test, 12.5 mgul indomethacin was added to the nightdwell and the test was performed with 25 mgul indomethacin. Results. In the normal dose indomethacin group, the dialysate concentrations of prostaglandin (PG) 6-keto-PGF 1a and thromboxane (Tx) TxB 2 were signi®cantly lower with indomethacin (IND) compared with the control dwell (C): 6-keto-PGF 1a median 93 (C) vs 7.5 (IND) ngul, Ps0.006 and TxB 2 12.3 (C) vs 9.0 (IND) ngul, Ps0.04. The dialysate concentration of PGE 2 was not different during the control dwell (68.5 ngul) compared with the indomethacin experiment (50.3 ngul, Ps0.5). The mass transfer area coef®cients (MTAC) of nitrate and cGMP, and parameters of nitric oxide synthesis, were similar during both experiments. The MTAC of creatinine and urate were not different with indomethacin: creatinine median 9.5 (C) vs 10.2 mlumin (IND), Ps0.2 and urate 7.2 (C) vs 7.3 mlumin (IND), Ps0.3. Only the MTAC of urea was marginally higher with indomethacin: 16.0 (C) vs 16.6 mlumin (IND), Ps0.04. No differences were found in the clearances of the macromolecules b2-microglobulin, albumin, IgG and a2-microglobulin. With the high indomethacin dose no inhibition of PGE 2 was found: 69 (C) vs 63 ngul(IND), not signi®cant. Furthermore, no differences were found in the transport rates of small solutes or proteins. This indicates no effect of indomethacin on the peritoneal surface area and the size-selective permeability to macromolecules. In both groups no effect was found on the transcapillary ultra®ltration and the effective lymphatic absorption rate during the 4-h dwell. Consequently, the net ultra®ltration, the difference between these, did not change. Conclusions. The indomethacin induced inhibition of the synthesis of 6-keto-PGF 1a and TxB 2 did not lead to alterations in functional parameters of the peritoneal surface area, the intrinsic permeability to macromolecules and¯uid kinetics. Therefore, these prostaglandins are not likely to be involved in the regulation of peritoneal transport during stable CAPD.
Introduction
The transport of solutes and¯uid across the peritoneal membrane during continuous ambulatory peritoneal dialysis (CAPD) is determined by its surface area and intrinsic permeability. The effective or functional peritoneal surface area is the part of the peritoneum that is actually involved in the transport of solutes. It is dependent on the splanchnic blood volume and so on the number of perfused peritoneal capillaries w1,2x. These are dynamic factors, implying that the effective surface area is variable. For example, instillation of dialysis solutions in¯uences the peritoneal transport capacity by vasodilation of the vessels of the peritoneal membrane w3,4x. Consequently, the peritoneal transport characteristics are signi®cantly higher during the initial phase of a dwell w5,6x. It is likely that locallyproduced vaso-active mediators will be involved in the regulation of the number and diameter of perfused peritoneal capillaries. Prostaglandins may be among these mediators as they can be synthesized by cultured human peritoneal mesothelial cells w7x. In the peritoneal cavity prostaglandins are locally produced w8,9x.
Both the vasodilating prostaglandins PGE 2 and 6-keto-PGF 1a and the vasoconstricting PGF 2a and thromboxane (Tx) TxB 2 have been detected in the ef¯uent of stable CAPD patients w10x. During peritonitis, a situation with vasodilation and increased peritoneal permeability, the concentrations of especially the vasodilating prostaglandins in the ef¯uent are markedly elevated w11,12x. Inhibition of local prostaglandin synthesis by intraperitoneal (i.p.) administration of indomethacin during the initial phase of peritonitis reduced the infection induced increased size-selective intrinsic permeability, but had no effect on the parameters of the effective peritoneal surface area w13x.
The aim of the present study was to investigate the role of locally produced prostaglandins in the regulation of peritoneal membrane characteristics during stable, non-infected CAPD. This was performed by i.p. administration of the same dose of indomethacin, to stable CAPD patients, that had proved to be effective during peritonitis and also of a higher dose during a longer time period. Furthermore, possible effects on the parameters of nitric oxide synthesis were determined.
Patients and methods

Patients
In 10 stable CAPD patients (four femaleusix male) two standard peritoneal permeability analyses (SPA) were performed within 1 week for testing the normal dose of indomethacin. The patients had a mean age of 53 years (range 29±75 years). They were treated with CAPD for 5±88 months (median 22 months). The causes for renal replacement therapy were hypertensive nephropathy (three patients), chronic glomerulonephritis (four patients) diabetic nephropathy (one patient), obstructive uropathy (one patient) and systemic lupus erythematosus (one patient). In ®ve other patients (all male) with a mean age of 58 years (range 50±64 years) a higher indomethacin dose was tested. These patients were treated with CAPD for 3±105 months. The causes for renal replacement therapy were hypertensive nephropathy (three patients), chronic glomerulonephritis (one patient) and obstructive uropathy (one patient). All patients performed CAPD using commercially available dialysate (Dianeal 1 , Baxter BV, Utrecht, The Netherlands). None of the patients had peritonitis at the time of the study or in the four preceding weeks. The protocol was approved by the Committee of Medical Ethics of the University Hospital of Amsterdam and informed consent was obtained from all patients after an explanation of the purpose and methods of the study.
Procedure
The SPAs were performed during 4-h dwell periods w14x. For testing the normal dose of indomethacin, both tests were done with 1.36% glucose dialysate (Dianeal 1 ), 1 day with and the other day without addition of 12.5 mgul indomethacin. To all test bags dextran 70 (Macrodex 1 , NPBI, EmmerCompascuum, The Netherlands) 1 gul was added to calculate peritoneal¯uid kinetics w15x. The sequence of both experiments had been randomized. Prior to instillation of the test solution, the peritoneal cavity was rinsed with 1.36% glucose dialysate. On the indomethacin day, 12.5 mgul indomethacin was also added to the rinsing bag. Samples were taken from the test dialysate before in¯ow and 10, 20, 30, 60, 120, 180 and 240 min after instillation of the test solution. To avoid a dead-space effect, 100±200 ml was temporarily drained before each sample was collected. After drainage of the test solution, the abdomen was rinsed again with 1.36% glucose dialysate. Samples from this rinsing bag were used for the calculation of the residual volume. Blood samples were drawn at the start and at the end of the test. Dextran 1 (20 ml, Promiten 1 , NPBI, Emmer-Compascuum, The Netherlands) was given intravenously (i.v.) after the ®rst blood sample to prevent possible anaphylaxis to dextran 70 w16x.
For testing the high-dose of indomethacin, 12.5 mgul indomethacin was added to the nightdwell, the night before the indomethacin experiment. Also 12.5 mgul indomethacin was added to the rinsing bag. The indomethacin-SPA was performed with 25 mgul indomethacin added to the test bag. The further procedure of the SPA was similar as described for the normal indomethacin dose.
Assays
Total dextran 70 was determined in all dialysate samples by means of high-performance liquid chromatography w17x. Both in plasma and dialysate urea, creatinine and urate were measured by enzymatic methods (Boehringer Mannheim, Mannheim, Germany). Beta-2 microglobulin was determined on an IMx system using a Microparticle Enzyme Immunoassay (Abbott laboratories, North Chicago, IL, USA). Albumin, IgG and a2-macroglobulin were determined by nephelometry (BN100, Behring, Marburg, Germany). Glucose was measured by glucose oxidase-peroxidase method using an auto analyzer (SMA-II, Technicon, Terrytown, USA).
Blood and dialysate samples for nitrite, nitrate and cGMP were centrifuged at 1530 g for 10 min and immediately stored at À208C. Nitrite and nitrate were measured by ion-pair high-performance liquid chromatography. cGMP was measured by an Enzyme Immunoassay (Cayman Chemical Company, Ann Arbor, USA).
The prostaglandins PGE 2 , 6-keto-PGF 1a , PGF 2a and TxB 2 were determined in dialysate by radioimmunoassays according to the method of Thomas et al. w18x with one modi®ca-tion: the samples were not puri®ed before the analysis, because puri®cation resulted in the same values for all prostaglandins w11x. The tritium labeled tracers were supplied by Dupont (Dreieich, Germany). Antiserum against PGE 2 was provided by Dr J. J. Pratt (Academic Hospital Groningen, The Netherlands). Antisera against 6-keto-PGF 1a , PGF 2a and TxB 2 were purchased from Cayman Chemical (Ann Arbor, USA). Cross-reactivity with the other prostaglandins was 4.3% for PGE 2 , 10.7% for 6-keto-PGF 1a , 5.3% for PGF 2a and 2.0% for TxB 2 . The lower detection limits were 18.0 ngul for PGE 2 , 4.5 ngul for 6-keto-PGF 1a and 9.0 ngul for PGF 2a and TxB 2 . The intra-assay variability was below 5.3%.
Calculations
The transport of the low-molecular-weight solutes was expressed as mass transfer area coef®cients (MTAC). This is the maximal theoretical clearance of a solute transported from the blood to the dialysate by diffusion at time zero, before solute transport has started. The MTACs of urea, creatinine, urate, nitrate and cGMP were calculated according to the model of Waniewski et al. w19x, with a correction factor for plasma water w20x. An MTAC that exceeds the value expected on the basis of the molecular weight of a solute points to local i.p. release of the solute.
Peritoneal clearances of b2-microglobulin, albumin, IgG and a2-macroglobulin were calculated using the equation:
where Cl is the clearance, D is the dialysate concentration, V is the dialysate volume, P is the plasma concentration and t is the dwell time. These clearances and the free diffusion coef®cients of the four proteins in water, were used to calculate the restriction coef®cient. The restriction coef®cient (RC) is the functional characterization of the intrinsic size-selective peritoneal permeability w6,21x. This parameter is the slope of the power relationship between the clearances of the above mentioned proteins (Cl ) and their free diffusion coef®cient in water (D 20,w ) when plotted on a double logarithmic scale:
RC . The transport of¯uid across the peritoneum was calculated as described previously by Imholz et al. w6x. Brie¯y,¯uid transport from the peritoneal cavity is assumed to be by transcapillary back ®ltration and also by uptake into the lymphatic system. The effective lymphatic absorption rate can be approximated as the disappearance rate of dextran 70 w22x. These calculations include all pathways of lymphatic drainage from the peritoneal cavity, both subdiaphragmatic and interstitial. The transcapillary ultra®ltra-tion was calculated from the dilution of dextran 70. The net ultra®ltration is the difference between the transcapillary ultra®ltration and the lymphatic absorption.
Results are given as median values and ranges. Wilcoxon matched pairs rank sum test were used for distribution free testing.
Results
Normal indomethacin dose
The dialysate with and without addition of indomethacin was well tolerated. The dialysate concentration of 6-keto-PGF 1a decreased after addition of indomethacin from 93 ngul (range 14±360 ngul) to 8 ngul (-5±12 ngul), Ps0.006 (Figure 1 ). With indomethacin dialysate TxB 2 decreased from 12 ngul (range 9±23 ngul) to 9 ngul (-9±19 ngul), Ps0.04 (Figure 1 ). The median decrease was 91% (range 78±94%) for 6-keto-PGF 1a and 33% (range 0±71%) for TxB 2 . No difference was found in the dialysate concentration of the prostaglandin E 2 after addition of indomethacin: control 69 ngul (-18±111 ngul), indomethacin 50 ngul (-18±104 ngul) (Figure 1) . Six patients had a decrease in dialysate PGE 2 concentrations. They were not different from the other four with regard to MTACs of low-molecular-weight solutes, protein clearances or the restriction coef®cient to macromolecules (data not shown). The PGF 2a concentration in dialysate was above the lower detection limit in four patients during the control experiment and was detectable in three patients after the addition of indomethacin: control range -9±14.5 ngul, with indomethacin -9±21 ngul.
The dialysate concentrations of nitrite were below the lower detection limit. The nitrate concentrations in the dialysate were 83.6 mmolul (21.1±341.8 mmolul) in the control dwell and 50.9 mmolul (18.6±142.0 mmolul) during the indomethacin dwell, Ps0.3. The cGMP concentrations in the dialysate were also not different: control 8 nmolul (5.9±49.4 nmolul) and with indomethacin 14.9 nmolul (6.8±53.0 nmolul), Ps0.3. Table 1 shows the MTACs of nitrate and cGMP in the control experiment and after the addition of indomethacin. No signi®cant differences were found.
The MTACs of urea, creatinine and urate are summarized in Table 1 . Only for urea a marginally greater MTAC was found with indomethacin. The MTAC values of creatinine and urate were similar with and without indomethacin. Also, no differences were found in the clearances of the proteins b2-microglobulin, albumin, IgG and a2-macroglobulin ( Table 1) . The restriction coef®cient to macromolecules did not change.
The transcapillary ultra®ltration and the effective lymphatic absorption rate during the 4-h dwell were similar with and without indomethacin (Figure 2 ). Consequently, the net ultra®ltration pro®le, the difference between these two, did not change.
High indomethacin dose
Because no differences were found in PGE 2 concentrations with the normal indomethacin dose, a higher dose during a longer time period was used in ®ve other patients. With indomethacin no difference was found in the dialysate concentration of PGE 2 : control 69 ngul (48±119) and indomethacin 63 ngul (57±87). Also, no differences were found in the MTACs of urea, creatinine and urate and the peritoneal clearances of the proteins b2-microglobulin, albumin, IgG and a2-macroglobulin ( Table 2 ). The restriction coef®cients to macromolecules were similar and no effects were found on the peritoneal¯uid kinetics ( Table 2) .
Discussion
The present study demonstrates that inhibition of the synthesis of 6-keto-PGF 1a and TxB 2 by i.p.-administered indomethacin had no effect on the peritoneal permeability characteristics during stable CAPD. Furthermore, no effect of indomethacin was found on parameters of nitric oxide synthesis, measured in this study. Indomethacin inhibits cyclooxygenase activity and blocks the conversion of arachidonic acid to biologically active prostanoids w9x. Cyclooxygenase catalyses the conversion of PGG 2 to PGH 2 . These endoperoxides have a short half-life time and are converted into biologically active prostaglandins and thromboxane A 2 . PGH 2 is converted into the vasodilating PGE 2 or into the vasoconstricting PGF 2a . The biosynthesis of prostacyclin (PGl 2 ) is catalysed by prostacyclin synthase, thromboxane synthase induces conversion of PGH 2 into TxA 2 . PGl 2 and TxA 2 are rapidly degraded to respectively 6-keto-PGF 1a and TxB 2 . These stable metabolites are usually measured as a representation of the active compounds.
The prostaglandins PGE 2 , 6-keto-PGF 1a , PGF 2a and TxB 2 have been detected in the ef¯uent of stable CAPD patients. Possible sources of prostanoids released into the dialysate are the mesothelial cells, macrophages, endothelial cells or ®broblasts. The mesothelial cells are capable to generate prostanoids in isolated peritoneum and in cell cultures w7,23,24x. Topley et al. w24x reported an increased prostanoid release by cultered human peritoneal mesothelial cells after incubation with supernatant from stimulated and unstimulated peritoneal macrophages. Peritoneal macrophages isolated from dialysate of CAPD patients during an infection free period were shown to secrete spontaneously the metabolites PGE 2 , 6-keto-PGF 1a and TxB 2 w25x. Also, endothelial cells and ®broblasts are able to produce prostaglandins w26±28x.
In the present study the prostaglandin concentrations in the dialysate during the 4-h dwells were low, and sometimes even below the lower detection limit. However, the i.p. administration of 12.5 mgul indomethacin resulted in a decrease in the dialysate concentrations of 6-keto-PGF 1a and TxB 2 . The expected inhibition of PGE 2 synthesis was not found. Also, with the high dose of indomethacin, no inhibition of PGE 2 synthesis was found. Again, no differences were seen in the transport of small solutes, protein clearances or¯uid kinetics. Therefore, the absence of inhibition of PGE 2 synthesis is unlikely to be a result of a too low dose of indomethacin. Furthermore, with the dose of 12.5 mgul we found marked inhibition of prostaglandin synthesis during peritonitis, a situation with increased prostaglandin release w13x. We analysed this in more detail by comparing the dialysate concentrations of the prostaglandins reported by Zemel et al. w13x in peritonitis during indomethacin, with those after recovery from the infection. The dialysate concentrations of 6-keto-PGF 1a and TxB 2 in that study were signi®cantly lower during indomethacin treatment than control values after recovery. However, this difference was not present for the dialysate concentrations of PGE 2 , which suggests that indomethacin is only able to inhibit augmented synthesis of PGE 2 . One other study about i.p. cyclooxygenase inhibition in stable CAPD patients has been published. Steinhauer and Schollmeyer w10x studied four CAPD patients after recovery of peritonitis and found that i.p. administration of 12.5 mgul indomethacin for 24 h only diminished the peritoneal generation of PGE 2 , while no effect was observed on the synthesis of other prostanoids and the peritoneal protein loss. These ®ndings are dif®cult to interpret because of the small number of patients.
CAPD-related peritonitis is a situation with increased dialysate concentrations of various in¯am-matory mediators, including prostaglandins w10,11,29x. It is accompanied by increases in the transport of solutes, pointing to a larger effective surface area and increased intrinsic peritoneal permeability w11,30x. In previous studies in CAPD patients during peritonitis, evidence was obtained that changes in dialysate PGE 2 concentrations were related to changes in intrinsic permeability, but not to changes in the effective surface area w11x. This was investigated both with a statistical method w11x and also by PGE 2 synthesis inhibition using i.p. indomethacin w13x. These ®ndings are in accordance with the present study where no inhibition of PGE 2 synthesis resulted in no changes in the intrinsic permeability. An absence of the effect of intraperitoneal indomethacin on the intrinsic permeability in stable uninfected CAPD patients may either mean that these prostaglandins are only involved in the regulation of vascular permeability during pathological conditions, or may be caused by insuf®cient inhibition of PGE 2 . However, the inability of a high dose of indomethacin to inhibit PGE 2 suggests that PGE 2 synthesis during stable CAPD is at a baseline level. This supports the ®rst mentioned possibility.
Nitric oxide may be involved in the release of PGE 2 , possibly by direct activation of cyclooxygenase w31x. We therefore investigated the effect of indomethacin on parameters of nitric oxide activity, such as nitrate and the mediator cyclic guanosine monophosphate (cGMP). We found no evidence in the present study that indomethacin had any effect on the nitric oxide system: dialysate concentrations of nitrite were below the detection limit and the MTACs for nitrate and cGMP concentrations were not affected by indomethacin.
It is concluded that during stable CAPD, one i.p. administration of indomethacin during 4-h dwells caused inhibition of the synthesis of 6-keto-PGF 1a and TxB 2 . However, a decrease in the release of these prostaglandins did not result in alterations in the effective peritoneal surface area, the intrinsic permeability to macromolecules and the¯uid kinetics. This is consistent with our previous reports during peritonitis indicating that 6-keto-PGF 1a and TxB 2 are not related to peritoneal transport kinetics. Although, theoretically, the indomethacin induced decrease in the vasodilating 6-keto-PGF 1a could be counteracted by the decrease in the vasoconstricting TxB 2 , we think this possibility less likely because the decrease in 6-keto-PGF 1a was more pronounced than that in TxB 2 , and because in general the effects of non-steroidal antiin¯ammatory drugs are more pronounced on the vasodilating than on the vasoconstricting prostaglandins. PGE 2 was related to intrinsic permeability during peritonitis, but this prostaglandin could not be inhibited by indomethacin in the present study, neither using a normal indomethacin dose, nor using a high dose. Also, no differences were found in parameters for nitric oxide synthesis. Therefore, 6-keto-PGF 1a and TxB 2 are not likely to be involved in the regulation of peritoneal transport during stable CAPD, while an effect of PGE 2 on the size-selectivity of the peritoneum is probably only present during acute peritonitis.
